Skip to main content
. 2023 Jan 23;13(4):688–700. doi: 10.34172/apb.2023.071

Table 2. ATP competitive inhibitors of GSK-3β in Alzheimer’s disease .

Drug Structure Mode of action
6-BIO

graphic file with name apb-13-688-g005.jpg

GSK-3β ATP competitive inhibition
Meridianins

graphic file with name apb-13-688-g006.jpg

GSK-3β ATP competitive inhibition
Amino pyrimidines

graphic file with name apb-13-688-g007.jpg

GSK-3β ATP competitive inhibition
Aryl indole maleimides

graphic file with name apb-13-688-g008.jpg

GSK-3β ATP competitive inhibition
Hymenialdisine

graphic file with name apb-13-688-g009.jpg

GSK-3β ATP competitive inhibition
Indirubins

graphic file with name apb-13-688-g010.jpg

GSK-3β ATP competitive inhibition
Pyrazines

graphic file with name apb-13-688-g011.jpg

GSK-3β ATP competitive inhibition
Phenyl methylene hydantoins

graphic file with name apb-13-688-g012.jpg

GSK-3β ATP competitive inhibition
Paullones

graphic file with name apb-13-688-g013.jpg

GSK-3β ATP competitive inhibition
Indirubin-3'-monoxime

graphic file with name apb-13-688-g014.jpg

GSK-3 ATP-competitive inhibition
AR-A014418

graphic file with name apb-13-688-g015.jpg

GSK-3 ATP-competitive inhibition
1-Azakenpaullone

graphic file with name apb-13-688-g016.jpg

GSK-3β ATP competitive inhibition